K. Chin, VK. Chand, DS. Nuyten. Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy.. „Ann Oncol”, Apr 2017. DOI: 10.1093/annonc/mdx170. PMID: 28407031.
JL. Gulley, A. Rajan, DR. Spigel, N. Iannotti i inni. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.. „Lancet Oncol”. 18 (5), s. 599-610, May 2017. DOI: 10.1016/S1470-2045(17)30240-1. PMID: 28373005.
K. Chin, VK. Chand, DS. Nuyten. Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy.. „Ann Oncol”, Apr 2017. DOI: 10.1093/annonc/mdx170. PMID: 28407031.
JL. Gulley, A. Rajan, DR. Spigel, N. Iannotti i inni. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.. „Lancet Oncol”. 18 (5), s. 599-610, May 2017. DOI: 10.1016/S1470-2045(17)30240-1. PMID: 28373005.